CLASS II ONGOING Device recall · Reported 6 Sep 2023 · FDA Enforcement Report

Atellica CH LDL Cholesterol- In vitro diagnostic use recalled

Siemens Healthcare Diagnostics is recalling Atellica CH LDL Cholesterol- In vitro diagnostic use in the quantitative determination of, distributed nationwide in the US. The recall was initiated on 10 Jul 2023 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesUnique Device Identification (UDI): 00630414611037 All Lot Numbers
Quantity recalled6733 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2472-2023
FDA event ID
92800
Recalling firm
Siemens Healthcare Diagnostics, Tarrytown, NY
Classification
Class II
Status
Ongoing
Recall initiated
10 Jul 2023
FDA classified
28 Aug 2023
Reported
6 Sep 2023
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

10 Jul 2023Recall initiated by company
28 Aug 2023Classified by FDA+49 days
6 Sep 2023Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Potential for reagent carryover on the Atellica CH 930 resulting in a positive bias that could impact quality control (QC), patient samples, and calibrator results with from Atellica¿ CH Total Bilirubin_2 (TBil_2), Atellica¿ CH LDL Cholesterol (LDLC), Atellica¿ CH Gamma-Glutamyl Transferase (GGT) and Atellica¿ CH HDL Cholesterol (HDLC)

Product as listed by the FDA

Atellica CH LDL Cholesterol- In vitro diagnostic use in the quantitative determination of LDL cholesterol in human serum and plasma (lithium heparin, EDTA, sodium heparin Test Code: LDLC Siemens Material Number (SMN): 11537214

Where it was distributed

US Nationwide - Worldwide Distribution Foreign: Taiwan Uruguay Vietnam

Nationwide

Questions about this recall

Why was it recalled?

Potential for reagent carryover on the Atellica CH 930 resulting in a positive bias that could impact quality control (QC), patient samples, and calibrator results with from Atellica¿ CH Total Bilirubin_2 (TBil_2), Atellica¿ CH LDL Cholesterol (LDLC), Atellica¿ CH Gamma-Glutamyl Transferase (GGT) and Atellica¿ CH HDL Cholesterol (HDLC)

Which lots are affected?

Unique Device Identification (UDI): 00630414611037 All Lot Numbers

Where was it sold?

US Nationwide - Worldwide Distribution Foreign: Taiwan Uruguay Vietnam

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

3 other products · FDA event 92800

This product is part of a recall event; the main page for the event is Atellica CH Gamma-Glutamyl Transferase-IIn vitro diagnostic recalled.

More recalls from Siemens Healthcare Diagnostics

All 694

Other Test Kits & Diagnostics recalls

All 2,656